The risk of liver enzyme elevation (LEE) after different ritonavir-boosted protease inhibitors (PI/r) has not been fully assessed in real-life settings and in populations with high rates of hepatitis C virus (HCV) coinfection.

Lapadula, G., Costarelli, S., Chatenoud, L., Castelli, F., Astuti, N., Di Giambenedetto, S., Quiros Roldan, E., Sighinolfi, L., Ladisa, N., Di Pietro, M., Zoncada, A., Di Filippo, E., Gori, A., Nasta, P., Torti, C., Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients, <<JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES>>, 2015; 69 (3): 312-318. [doi:10.1097/QAI.0000000000000585] [http://hdl.handle.net/10807/68425]

Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients

Di Giambenedetto, Simona;
2015

Abstract

The risk of liver enzyme elevation (LEE) after different ritonavir-boosted protease inhibitors (PI/r) has not been fully assessed in real-life settings and in populations with high rates of hepatitis C virus (HCV) coinfection.
Inglese
Lapadula, G., Costarelli, S., Chatenoud, L., Castelli, F., Astuti, N., Di Giambenedetto, S., Quiros Roldan, E., Sighinolfi, L., Ladisa, N., Di Pietro, M., Zoncada, A., Di Filippo, E., Gori, A., Nasta, P., Torti, C., Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients, <>, 2015; 69 (3): 312-318. [doi:10.1097/QAI.0000000000000585] [http://hdl.handle.net/10807/68425]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/68425
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 11
social impact